First ever evidence of treatment-induced reduction in HIV reservoirs

ABX464, ABIVAX’ lead drug candidate, impacted HIV blood reservoir in a Phase IIa clinical trial (ABX464-004)

  • Preliminary clinical trial results support ABX464’s potential to become a key functional cure element for HIV
  • Additional Phase IIa trial already ongoing to study ABX464 effects on the HIV reservoir in gut tissue
  • ABIVAX highly committed to further development for potential benefit to HIV patients
  • Data strengthens potential of ABIVAX’ antiviral discovery platfo­rm

Paris, May 2nd, 2017 at 8:00am CEST – ABIVAX (Euronext Paris: FR0012333284 – ABVX) is an innovative biotechnology company targeting the immune system to eliminate viral diseases using its unique technology platform. ABIVAX announced today that the company’s lead therapeutic candidate ABX464 demonstrated the first reduction in HIV reservoirs ever observed in chronically infected HIV patients as measured by total HIV DNA detected in peripheral blood mononuclear cells (PBMCs).

“This is the first time we see a signal with any therapeutic candidate that it may be possible to reduce HIV reservoirs in patients,” said Professor Linos Vandekerckhove, Head HIV Cure Research Center at the Department of Internal Medicine, at the University of Ghent, Belgium, a principal investigator involved in the study. ‘’Now we are looking forward to learn how this drug can be optimized to be part of a multitarget approach to further reduce the viral reservoir” 

“We are excited to see this unique finding and are looking forward to further studying ABX464 as we would like to determine, through additional clinical trials, whether we can further increase the magnitude of the effect on reducing HIV reservoirs to the lowest possible level,” said Professor Bonaventura Clotet, Director of the IrsiCaixa AIDS Research Institute at the University Hospital Germans Trias i Pujol in Badalona, Barcelona, one of the largest HIV treatment centers in Europe and a principal investigator involved in the study.

In the ABX464-004 trial, 30 HIV patients were enrolled in Spain, Belgium and France. Patients were enrolled in a 3:1 randomization, receiving either ABX464 or matching placebo in addition to their current antiretroviral treatment during 28 days. The viral load at the start of the study was well controlled with boosted darunavir. After the 28-day treatment period, all treatments were interrupted until viral load rebound. Baseline and day 28 blood samples were taken in order to assess the potential effect of ABX464 on the HIV reservoir in PBMCs. The clinical trial has been completed with respect to patient treatment and follow-up.

Safety was the primary endpoint in the trial and ABX464 was well tolerated and there were no severe adverse events in the treatment group. Amongst evaluable patients (4 placebo and 14 ABX464-treated patients), a reduction in viral DNA copies/mPBMCs was observed in 7/14 treated patients (mean change of -40%, ranging from -27% to -67%) and no responders were observed in the placebo group. Responders were defined as patients who had a decrease greater than 25% in total HIV DNA in PBMCs and a reduction of at least 50 copies.

Total HIV DNA in PBMC has been validated as a widely accepted biomarker for measuring the HIV reservoir. Specifically, in untreated patients, total HIV DNA load influences the course of the infection and is therefore clinically relevant[1]. In addition, a correlation exists between the pool of HIV-1 DNA and the replication-competent reservoir[2].

Dr Jean-Marc Steens, Chief Medical Officer at ABIVAX said: “These results in patients are a first and very important step in supporting the hypothesis that ABX464 could impact the HIV reservoir. Currently approved drugs can effectively reduce and control the replication of the HIV virus in humans, allowing many patients to live with chronic treatment, but no drugs have been able to eradicate the virus in humans because it evades therapy by hiding in what have been called by the scientific community “HIV reservoirs”. In this Phase IIa clinical trial, during which patients were treated only for a short period of 28 days, we did not yet see an impact on the time to rebound after treatment interruption. Therefore, the next step will be to evaluate longer treatment duration with ABX464, which could lead to a profound reduction of the HIV reservoir and potentially become part of a functional cure for HIV patients.”

A separate Phase IIa clinical trial (ABX464-005) has already started to study the effects of ABX464 on HIV reservoirs in gut tissues. In this previously announced study, patients are receiving ABX464 for 28 days in addition to their antiretroviral treatment. Rectal biopsies are being collected at certain intervals, allowing quantification of the viral load and level of inflammation in the reservoir over time. Based on the results of the ABX464-004, ABIVAX plans to amend the ABX464-005 protocol to extend the treatment period in order to observe the longer-term effects of ABX464 on HIV reservoir suppression. Initial results of the ABX464-005 study are expected in Q3 2017.

“Based on this first ever clinical evidence that HIV reservoirs can be impacted in patients, we embrace the deep responsibility we have towards all HIV patients and the HIV community in driving this unique compound forward as rapidly as possible. Clearly, more research and clinical evidence are needed in order to achieve this goal,” said Prof. Hartmut Ehrlich, M.D., CEO of ABIVAX. “In addition, these exciting data provide further validation of ABIVAX’ antiviral platform technology in being able to generate product candidates against a number of other viral diseases with a high medical need, such as dengue, influenza and respiratory syncytial virus (RSV) disease, and also, based on the anti-inflammatory properties of ABX464, the opportunity for this molecule in inflammatory bowel diseases.”

The final data of ABX464-004 will be submitted for presentation at upcoming International HIV conferences and will be posted on


ABIVAX’s senior management will host a webcast presentation on May 2, 2017 at 4:00 pm CET (Paris time), to present and discuss the new data. The webcast presentation can be accessed via the following link:,and attendees can log on using the following telephone information:

Confirmation Code:  9467551

Participants, Local - Paris, France:

+33(0)1 76 77 22 32

Participants, Local - Vienna, Austria:

+43(0)1 25302 1771

Participants, Local - New York, United States of America:

+1646 254 3368

Participants, Local - London, United Kingdom:

+44(0)20 3427 1927

Participants, Local - Geneva, Switzerland:

+41(0)22 567 5429

Participants, Local - Dublin, Ireland:

+353(0)1 2465605

Participants, Local - Milan, Italy:

+3902 3600 8000

Participants, Local - Madrid, Spain:

+3491 375 3083

Participants, Local - Brussels, Belgium:

+32(0)2 400 1973

Participants, Local - Frankfurt, Germany:

+49(0)69 2999 3285

Participants, Local - Amsterdam, Netherlands:

+31(0)20 721 9157

Participants, Local - Stockholm, Sweden:

+46(0)8 5065 3932

[1]Avettand-Fènoël et al: Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical

Implications. Clin. Microbiol. Rev. 29, 859-880 (2016).

[2]Kiselinova et al : Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth. PLOS Pathogens DOI:10.1371/journal.ppat.1005472 (2016).

Press contacts

Caroline Carmagnol 
Margaux Pronost
+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41